Skip to search formSkip to main contentSkip to account menu

Rocuronium

Known as: 1-(17-(acetoyl)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)pyrrolidinium 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (2)

AndrostanolsNeuromuscular Nondepolarizing Agents

Narrower (5)

EsmeronORG-9426Zemuronrocuronium bromide
Rocuronium Ab.IgE:ACnc:Pt:Ser:QnRocuronium leukotriene release:MCnc:Pt:WBC:Qn

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial
Background and objective Sugammadex, a modified γ-cyclodextrin, is a selective relaxant-binding agent designed to reverse the… 
Highly Cited
2010
Highly Cited
2010
Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study.
BACKGROUND Sugammadex is a selective relaxant binding agent designed to encapsulate the neuromuscular blocking agent, rocuronium… 
Review
2010
Review
2010
Intraosseous Infusions: A Review for the Anesthesiologist with a Focus on Pediatric Use
Intraosseous (IO) access is used most frequently for emergency care of critically ill infants and children when IV access cannot… 
Highly Cited
2009
Highly Cited
2009
Reversal of Profound Neuromuscular Block by Sugammadex Administered Three Minutes after Rocuronium: A Comparison with Spontaneous Recovery from Succinylcholine
Background:Rocuronium in intubation doses provides similar intubation conditions as succinylcholine, but has a longer duration of… 
Highly Cited
2007
Highly Cited
2007
Sugammadex Reversal of Rocuronium-Induced Neuromuscular Blockade: A Comparison with Neostigmine–Glycopyrrolate and Edrophonium–Atropine
BACKGROUND:Sugammadex is a modified γ cyclodextrin compound, which encapsulates rocuronium to provide for a rapid reversal of… 
Highly Cited
2007
Highly Cited
2007
A Randomized, Dose-Finding, Phase II Study of the Selective Relaxant Binding Drug, Sugammadex, Capable of Safely Reversing Profound Rocuronium-Induced Neuromuscular Block
BACKGROUND:The reversal of a deep neuromuscular blockade remains a significant clinical problem. Sugammadex, a modified &ggr… 
Highly Cited
2006
Highly Cited
2006
Reversal of Rocuronium-induced Neuromuscular Block by the Selective Relaxant Binding Agent Sugammadex: A Dose-finding and Safety Study
Background: Sugammadex (Org 25969) forms a complex with steroidal neuromuscular blocking agents, thereby reversing neuromuscular… 
Highly Cited
2004
Highly Cited
2004
Épidémiologie des réactions anaphylactiques et anaphylactoïdes peranesthésiques en France. Septième enquête multicentrique (Janvier 2001–Décembre 2002)
Review
2001
Review
2001
Anaphylaxis during anaesthesia. Results of a two-year survey in France.
Between January 1, 1997 and December 31, 1998, 467 patients were referred to one of the allergo-anaesthesia centres of the French… 
Review
1999
Review
1999
Épidémiologie des réactions anaphylactoïdes peranesthésiques. Quatrième enquête multicentrique (juillet 1994-décembre 1996)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)